Highlights NFL Biosciences

Equities

ALNFL

FR0014003XT0

Market Closed - Euronext Paris Other stock markets 16:35:14 17/05/2024 BST			5-day change	1st Jan Change
2.18 ^EUR	+1.40%		+6.34%	+51.39%

04-12	Global markets live: BP, Apple, Vodafone, Ford, Lockheed Martin...
04-12	NFL Biosciences: successful capital increase	CF

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Global markets live: BP, Apple, Vodafone, Ford, Lockheed Martin...	04-12
NFL Biosciences: successful capital increase	04-12	CF
NFL Biosciences Raises EUR3 Million for Clinical Trial, Partnerships	04-12	MT
NFL Biosciences: success of smoking cessation study	01-30	CF
NFL Biosciences Announces Patent Application Filed in the United States for Reducing Alcohol Consumption with NFL-301 & Preparation of a Pre-Ind Application Submission with the FDA	18/07/23	CI
Changes in the governance of NFL Biosciences	27/02/23	GL
Changes in the governance of NFL Biosciences	27/02/23	AQ
NFL BIOSCIENCES Announces Inclusion of the First Volunteer in the PRECESTO Study	22/02/23	CI
NFL Biosciences Announces CESTO II Trial Progressing on Schedule	20/01/23	CI
NFL Biosciences SA Announces Clinical Trial Approved to Demonstrate the Complementarity of NFL-101 with Other Smoking Cessation Treatments	08/11/22	CI
NFL Biosciences: 2022 first-half business and earnings	25/10/22	GL
Themis Medicare Partners with NFL Biosciences to Develop Anti-Smoking Drug in India	07/10/22	MT
NFL Biosciences Partners with Themis Medicare for the Development of NFL-101 in India	05/10/22	CI
NFL Biosciences SA and ATHENA Pharmaceutiques Announces to Set Up Co-Development Agreement	02/02/22	CI
NFL Biosciences SA Announces Phase II/III Clinical Trial Launched for Smoking Cessation	14/12/21	CI
NFL Biosciences SA and Diverchim Announces Partnership	17/11/21	CI
NFL Biosciences SA Announces Earnings Results for the Six Months Ended June 30, 2021	04/10/21	CI
NFL Biosciences : Receives US Patent for Tobacco Addiction Treatment Candidate	22/09/21	MT
Global markets live: Thales, Nestlé, Evergrande, AMC, Walmart...	16/09/21
French National Agency for the Safety of Medicines and Health Products Approves NFL Biosciences's Phase II/III Clinical Trial to Assess the Efficacy and Safety of Its NFL-101 Smoking Cessation Treatment	15/09/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NFL Biosciences

Equities

ALNFL

FR0014003XT0

Highlights

Filters